NRX Pharmaceuticals, Inc.: 10-Q filed 2020-05-15

Name: NRX Pharmaceuticals, Inc.: 10-Q filed 2020-05-15
Creator: NRX Pharmaceuticals, Inc.

What NRX Pharmaceuticals, Inc. reported in its quarterly report filed 2020-05-15 (fiscal Q1 2020): 19 published measures, 40 facts as tagged in accession 0001654954-20-005634.

This filing

Form: 10-Q (quarterly report)
Filed: 2020-05-15
Fiscal period: fiscal Q1 2020
Accession: 0001654954-20-005634 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All NRX Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2020-03-31	6,272,781	USD
At 2019-12-31	32,074,694	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2020-03-31	2,497,037	USD
At 2019-12-31	2,574,205	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2020-03-31	3,775,744	USD
At 2019-12-31	5,000,001	USD
At 2019-03-31	5,000,005	USD
At 2018-12-31	5,000,006	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2020-01-01 to 2020-03-31	273,220	USD	91
2019-01-01 to 2019-03-31	187,965	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2020-01-01 to 2020-03-31	-76,434	USD	91
2019-01-01 to 2019-03-31	-297,696	USD	90

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2020-01-01 to 2020-03-31	-25,769,073	USD	91
2019-01-01 to 2019-03-31	796,642	USD	90

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2020-01-01 to 2020-03-31	25,926,275	USD	91
2019-01-01 to 2019-03-31	-508,207	USD	90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2020-03-31	642,715	USD
At 2019-12-31	369,495	USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2020-01-01 to 2020-03-31	72,628	USD	91
2019-01-01 to 2019-03-31	31,716	USD	90

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2020-01-01 to 2020-03-31	-119,300	USD	91
2019-01-01 to 2019-03-31	-163,181	USD	90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2020-03-31	80,774	USD
At 2019-12-31	69,489	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2020-03-31	316,381	USD
At 2019-12-31	622,441	USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

Period	Value	Unit	Days
2020-01-01 to 2020-03-31	25,997,965	USD	91
2019-01-01 to 2019-03-31	0	USD	90

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2020-01-01 to 2020-03-31	119,300	USD	91
2019-01-01 to 2019-03-31	163,181	USD	90

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2020-03-31	2,716,028	shares
At 2019-12-31	2,844,414	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2020-03-31	3,130,313	USD
At 2019-12-31	4,627,662	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2020-01-01 to 2020-03-31	345,848	USD	91
2019-01-01 to 2019-03-31	219,681	USD	90

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2020-01-01 to 2020-03-31	273,220	USD	91
2019-01-01 to 2019-03-31	-84,422	USD	90

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2020-01-01 to 2020-03-31	465,148	USD	91
2019-01-01 to 2019-03-31	382,862	USD	90

Inspect the source

Entity: NRX Pharmaceuticals, Inc. / CIK 0001719406
Captured: 2026-09-21T17:27:10.215Z
SEC response SHA-256: 6397c43beff03c5cfffaefec8f7831ab311854b7252e2db1d5c35f1cb8b83bdf

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001719406.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))